Current Report Filing (8-k)
May 23 2016 - 5:14PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT
REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of report (Date of earliest event reported): May
23, 2016
ORAMED PHARMACEUTICALS INC.
|
(Exact name of registrant as specified in its charter)
|
DELAWARE
|
|
001-35813
|
|
98-0376008
|
(State or Other Jurisdiction
|
|
(Commission
|
|
(IRS Employer
|
of Incorporation)
|
|
File Number)
|
|
Identification No.)
|
Hi-Tech Park 2/4 Givat Ram, PO Box 39098, Jerusalem, Israel
|
|
91390
|
(Address of Principal Executive Offices)
|
|
(Zip Code)
|
+972-2-566-0001
(Registrant’s telephone number, including area
code)
Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ Written communications pursuant to Rule 425 under the Securities
Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange
Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under
the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under
the Exchange Act (17 CFR 240.13e-4(c))
ITEM 7.01.
|
REGULATION FD DISCLOSURE.
|
Oramed Pharmaceuticals Inc. has posted an updated corporate presentation
to its website. A copy of the presentation is furnished with this Current Report on Form 8-K as Exhibit 99.1 and is incorporated
herein by reference.
ITEM 9.01.
|
FINANCIAL STATEMENTS AND EXHIBITS.
|
|
99.1
|
Corporate Presentation
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
ORAMED
PHARMACEUTICALS INC.
|
|
|
May
23, 2016
|
By:
|
/s/
Nadav Kidron
|
|
Name:
|
Nadav
Kidron
|
|
Title:
|
President
and CEO
|
3
Oramed Pharmaceuticals (NASDAQ:ORMP)
Historical Stock Chart
From Mar 2024 to Apr 2024
Oramed Pharmaceuticals (NASDAQ:ORMP)
Historical Stock Chart
From Apr 2023 to Apr 2024